Ovallath Sujith, Sulthana Bahiya
James Parkinson's Movement Disorder Research Centre, Kannur Medical College, Kannur, Kerala, India.
Ann Indian Acad Neurol. 2017 Jul-Sep;20(3):185-189. doi: 10.4103/aian.AIAN_241_17.
Levodopa - the aromatic amino acid L-3,4-dihydroxy phenylalanine has held the attention of neurologists and pharmacologists alike for more than half a century. Even though extensive research has been done across the globe in treatment of Parkinson's disease, with different molecules, none could replace the gold standard treatment or provide complete relief for the debilitated. Although research brought us better tips and tricks to modulate the dopamine blood levels to balance between the desired and deleterious effects, it could never replace the basic substrate. From simple oral preparation to more advanced treatment like duodenal dopa administration for better efficacy and compliance, L-dopa has sure undergone scrutiny and stayed strong as the fundamental neurotransmitter replacement therapy to pave path for many more new therapeutic strategies. So as a token of gratitude to the revolutionary agent and pioneers behind it, a trip down the memory lane is in order.
左旋多巴——芳香族氨基酸L-3,4-二羟基苯丙氨酸,半个多世纪以来一直吸引着神经学家和药理学家的关注。尽管全球范围内针对帕金森病的治疗已经进行了广泛研究,涉及不同分子,但没有一种能够取代这一黄金标准治疗方法,也无法为患者提供完全缓解。尽管研究为我们带来了更好的方法来调节多巴胺血药浓度,以平衡预期效果和不良影响,但始终无法替代基本底物。从简单的口服制剂到更先进的治疗方法,如十二指肠给予多巴以提高疗效和依从性,左旋多巴无疑经受住了审视,并作为基本的神经递质替代疗法保持强劲势头,为更多新的治疗策略铺平道路。因此,为了向这一革命性药物及其背后先驱者表达敬意,回顾一下历史很有必要。